Lantheus Holdings, INC 8-K filings

NASDAQ

2 May 2024

LNTH

8-K: Lantheus Holdings Reports Strong First Quarter 2024 Results, Raises Full-Year Guidance

Lantheus Holdings announced a 23% increase in worldwide revenue for the first quarter of 2024, driven by strong sales of PYLARIFY and DEFINITY, and raised its full-year revenue and earnings guidance.

NASDAQ

29 Apr 2024

LNTH

Lantheus Holdings, INC

8-K: Lantheus Holdings Increases Share Reserve in Equity Incentive Plan Following Annual Meeting

Lantheus Holdings has increased the number of shares reserved for issuance under its 2015 Equity Incentive Plan by 4,000,000 shares, following approval at the Annual Meeting of Stockholders.

NASDAQ

22 Feb 2024

LNTH

Lantheus Holdings, INC

8-K: Lantheus Holdings Reports Record Revenue and Earnings for Full Year 2023, Provides Positive 2024 Guidance

Lantheus Holdings announced strong financial results for the fourth quarter and full year 2023, with significant increases in revenue and earnings, and provided optimistic guidance for 2024.

NASDAQ

26 Jan 2024

LNTH

Lantheus Holdings, INC

8-K: Lantheus Faces Patent Infringement Lawsuit Over Generic Cancer Drug

Lantheus Holdings is being sued by Novartis for patent infringement related to its generic version of the cancer drug LUTATHERA.

NASDAQ

23 Jan 2024

LNTH

Lantheus Holdings, INC

8-K: Lantheus Announces CEO Succession Plan: Brian Markison to Take Helm as Mary Anne Heino Transitions to Board Chair

Lantheus Holdings, Inc. has announced a leadership transition, with Brian Markison appointed as CEO effective March 1, 2024, and Mary Anne Heino becoming Chair of the Board.